Study investigator presents positive efficacy data in ongoing retinal disease clinical trial

14 October 2019: ReNeuron Group plc (AIM: RENE), a global leader in the development of cell-based therapeutics, is pleased to announce that positive efficacy data were presented during the weekend at the American Academy of Ophthalmology Annual Meeting (AAO) in San Francisco from the Company’s Phase 1/2a clinical trial of its hRPC stem cell therapy in retinitis pigmentosa (RP).

Read more…

To view the presentation please CLICK HERE.